68 results
8-K
EX-99.1
CSTL
Castle Biosciences Inc
2 May 24
Castle Biosciences Reports First Quarter 2024 Results
4:08pm
portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research … and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy
S-3
CSTL
Castle Biosciences Inc
28 Feb 24
Shelf registration
5:08pm
purposes, including research and development expenses, selling, general and administrative expenses and manufacturing expenses. See “Use of Proceeds … to use the net proceeds from the sale of the securities offered hereby for general corporate purposes, which may include research and development, capital expenditures
8-K
EX-99.1
o0ocxprhsmadj
28 Feb 24
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
4:07pm
8-K
EX-99.2
628 610gk
8 Jan 24
Results of Operations and Financial Condition
7:04am
8-K
EX-99.1
n1rtd0rdrs 58n
2 Nov 23
Castle Biosciences Reports Third Quarter 2023 Results
4:09pm
8-K
EX-99.1
7pdczt
2 Aug 23
Castle Biosciences Reports Second Quarter 2023 Results
4:10pm
8-K
EX-99.1
s5bnaxaydkszt
3 May 23
Castle Biosciences Reports First Quarter 2023 Results
4:10pm
8-K
EX-99.1
4opp5id
2 Nov 22
Castle Biosciences Announces Third Quarter 2022 Results
4:24pm
8-K
EX-99.2
gb5qkdxz u5
8 Aug 22
Castle Biosciences Reports Second Quarter 2022 Results
4:12pm
8-K
EX-99.1
io5vkdi bvlh
8 Aug 22
Castle Biosciences Reports Second Quarter 2022 Results
4:12pm
S-3ASR
wpw7p2 z7
3 Jun 22
Automatic shelf registration
9:32pm
8-K
EX-99.1
kb3dbxf4miqja6edj2y
3 Jun 22
Other Events
5:27pm